Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Green Thumb IndustriesGTBIF -3.46%85 Return-on-Tangible-Equity is 7.02% as of Mar. 2026, which is 24% below its 10-year median of 9.24. GuruFocus rates GTBIF with a GF Score™ of 85/100 and a GF Value™ of $8.91 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 901 Drug Manufacturers companies, Green Thumb Industries ranks better than 69.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Green Thumb Industries's annualized net income for the quarter that ended in Mar. 2026 was $62 Mil. Green Thumb Industries's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $877 Mil. Therefore, Green Thumb Industries's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 7.02%.
The historical rank and industry rank for Green Thumb Industries's Return-on-Tangible-Equity or its related term are showing as below:
GTBIF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -389.1 Med: 9.24 Max: 34.72
Current: 14.99
During the past 13 years, Green Thumb Industries's highest Return-on-Tangible-Equity was 34.72%. The lowest was -389.10%. And the median was 9.24%.
GTBIF's Return-on-Tangible-Equity is ranked better than 69.92% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs GTBIF: 14.99
Green Thumb Industries (OTCPK:GTBIF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Green Thumb Industries Return-on-Tangible-Equity Related Terms
Green Thumb Industries Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Green Thumb Industries's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Green Thumb Industries Return-on-Tangible-Equity Chart
GTBIF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Green Thumb Industries's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Green Thumb Industries Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Green Thumb Industries's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Green Thumb Industries's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.02% mean?
Green Thumb Industries (GTBIF) has a Return-on-Tangible-Equity of 7.02% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Green Thumb Industries and its competitors. This is 24% below median its historical median of 9.24. According to the industry distribution chart, Green Thumb Industries ranks #271 out of 901 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Green Thumb Industries' Return-on-Tangible-Equity too high?
Green Thumb Industries' current Return-on-Tangible-Equity of 7.02% is 24% below median its 10-year median of 9.24. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Green Thumb Industries' value of 7.02% is 11.1% below this industry median. Based on the distribution chart, Green Thumb Industries ranks #271 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Green Thumb Industries has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Green Thumb Industries' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Green Thumb Industries ranks #271 out of 901 companies for Return-on-Tangible-Equity. This puts Green Thumb Industries in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Green Thumb Industries' value of 7.02% is 11.1% below this benchmark. While the company's 10-year median is 9.24 vs. the industry median of 7.90, Green Thumb Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Green Thumb Industries's current Return-on-Tangible-Equity of 7.02% is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Green Thumb Industries and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Green Thumb Industries's current Return-on-Tangible-Equity is 7.02%, which is 24% below median its own 10-year median of 9.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Green Thumb Industries stock overvalued right now?
Based on GuruFocus' analysis, Green Thumb Industries (GTBIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.91, compared to a current price of $7.26 — trading 18.5% below its estimated fair value. The current Return-on-Tangible-Equity is 7.02%, which is 24% below median its 10-year median of 9.24 and 11.1% below the Drug Manufacturers industry median of 7.90. Green Thumb Industries' overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Green Thumb Industries (GTBIF), the current Return-on-Tangible-Equity is 7.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Green Thumb Industries (GTBIF) Overvalued in 2026?
Based on GuruFocus' analysis, Green Thumb Industries stock appears to be undervalued.
The current stock price of $7.26 is trading 18.5% below its estimated GF Value™ of $8.91.
GuruFocus considers Green Thumb Industries to be Modestly Undervalued.
Key valuation signals for GTBIF:
Return-on-Tangible-Equity: 7.02% (24% below median its 10-year median of 9.24)
GF Value™: $8.91 vs. price of $7.26 (18.5% below fair value)
Industry Position: 11.1% below the Drug Manufacturers median (#271 of 901)
No single metric tells the full story. See the GTBIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Green Thumb Industries is headquartered in Chicago, Illinois, and produces and sells medicinal and recreational cannabis through wholesale and retail channels in the United States. It has a presence in 14 states and operates more than 100 cannabis stores under the brand Rise. GTI is focusing its expansion on limited-license states with large populations, and it does not currently export into the global medical market due to the USA federal prohibition. It offers multiple products under a portfolio of cannabis consumer packaged goods brands, including &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, Incredibles, and RYTHM.
85GF Score
Get the complete analysis for GTBIF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GTBIF has been successfully added to your 
